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OBJECTIVES We sought to study the association of the silent cerebral infarct (SCI), a predisposing
condition of stroke, with hyperinsulinemia and hemostatic abnormalities in older hyperten-
sive subjects.
BACKGROUND Hypertension is a powerful risk factor for stroke. However, the role of other risk factors for
stroke in hypertensive subjects remains incompletely understood.
METHODS We performed brain magnetic resonance imaging and measured cardiovascular risk
factors, by administering the 75-g oral glucose tolerance test and measuring plasma
insulin and hemostatic variables, in 123 asymptomatic hypertensive subjects (mean age 69
years).
RESULTS At least one SCI was detected in 80 subjects (65%), and multiple SCIs were found in 48
subjects (39%). The presence of SCIs was associated with older age, higher levels of 24-h
systolic blood pressure, 2-h insulin, thrombin-generation markers (prothrombin fragment
112 and thrombin-antithrombin complexes), plasminogen activator inhibitor-1 (PAI-1),
D-dimer and von Willebrand factor (vWF), but not with plasmin-alpha2-plasmin complex
(PIC) levels. The 2-h insulin area under the curve (AUC) was positively correlated with
PAI-1 and vWF levels (p , 0.01), and the PAI-1 level was negatively correlated with the PIC
level (p , 0.02). Multiple logistic regression analysis revealed that age and the 2-h insulin
AUC were significantly associated with SCIs, particularly those located in the subcortical
white matter, and hemostatic abnormalities were significantly associated with the presence of
multiple SCIs, particularly those located in the basal ganglia.
CONCLUSIONS In older asymptomatic hypertensive subjects, hyperinsulinemia appears to be associated with
lacunar-type SCIs, particularly those located in the subcortical white matter, and hemostatic
abnormalities show an association with the presence of multiple SCIs, particularly those
located in the basal ganglia. (J Am Coll Cardiol 2001;37:871–7) © 2001 by the American
College of Cardiology
Hypertension is a powerful risk factor for stroke. However,
the role of other risk factors for stroke in hypertensive
subjects remains incompletely understood. In hypertensive
subjects, clustering abnormalities of lipid and glucose me-
tabolism and impaired fibrinolysis have been reported as a
part of insulin resistance syndrome (1,2). Insulin resistance
syndrome and hemostatic abnormalities (imbalance between
coagulation and fibrinolysis) have been proposed as new risk
factors for cardiovascular events (1). Plasma insulin profiles
are indicators of insulin resistance syndrome, and hyperin-
sulinemia is related to impaired fibrinolysis (3,4). Fibrino-
lytic activity is determined by the balance between tissue-
type plasminogen activator (t-PA) and plasminogen
activator inhibitor-1 (PAI-1), both of which are synthesized
and secreted from endothelial cells (ECs). Endothelial cell
damage also affects the imbalance in fibrinolysis.
Unlike coronary artery disease, the effects of insulin
resistance syndrome, hemostatic abnormalities and EC
damage on stroke have not yet been thoroughly investi-
gated. The silent cerebral infarct (SCI) is now thought to
be a predisposing condition for clinically overt stroke (5).
One prospective study demonstrated that SCI was a
strong predictor of subsequent clinically overt stroke,
with an odds ratio of ;10 (6). As hemostatic factors and
EC factors are complicated by changes that occur due to
brain tissue damage after clinical stroke events (7,8), we
used SCI as a surrogate model for ischemic stroke,
because such minor brain damage is less likely to influ-
ence hemostatic and EC factors. We have recently found
increased thrombin generation in SCIs of elderly subjects
with risk factors (9). However, there are no reports on the
relationships between hyperinsulinemia, hemostatic ab-
normalities and SCI in asymptomatic hypertensive sub-
jects.
To study these relationships, we performed the 75-g
oral glucose tolerance test (OGTT) and brain magnetic
resonance imaging (MRI) and measured insulin and
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hemostatic variables in asymptomatic elderly hyperten-
sive patients.
METHODS
Patients
We studied 123 asymptomatic hypertensive subjects (age
$55 years, range 55 to 88) who were recruited from
outpatient clinics. Hypertension was diagnosed when clin-
ical systolic blood pressure was consistently $140 mm Hg
and/or clinical diastolic blood pressure was $90 mm Hg at
three or more visits. Clinical blood pressure was measured in
the sitting position after the subject had rested for at least
5 min. The subjects were referred to the clinics because of
high blood pressure, were identified from population-based
screening for cardiovascular risk factors or were treated for
mild hypertension (they had agreed to stop antihypertensive
medications for ambulatory blood pressure monitoring and
blood testing, n 5 27). None of the patients had received
antihypertensive or lipid-lowering medications for at least
two weeks before this study. Of the 123 subjects studied, 77
(63%) had a history of antihypertensive treatment. Excluded
from this study were patients with renal failure (serum
creatinine . 106 mmol/liter), hepatic damage or obvious
present and/or previous coronary artery disease, stroke,
congestive heart failure, atrial fibrillation or malignancy.
Patients who showed signs of overt diabetes mellitus (fast-
ing glucose .7.8 mmol/liter and/or hemoglobin A1c
.6.4%) were also excluded. All of the subjects were ambu-
lant and had a normal appetite. The results of the physical
examination and laboratory studies (blood and urine tests,
chest X-ray and rest electrocardiography) were normal. No
cervical bruit was audible in the subjects. Smokers and
nonsmokers were defined by their current smoking status.
Body mass index was calculated as weight (kg)/height (m2).
Written, informed consent was obtained from all subjects.
This study was approved by the Research Ethics Commit-
tee, Department of Cardiology, Jichi Medical School, Japan.
Brain MRI and Patient Classification
Brain MRI was carried out with a 1.5-tesla MRI unit
(Toshiba MRT200FXII, Tokyo, Japan). The brain was
imaged in the axial plane at 8-mm slice thickness. An SCI
was defined exclusively as a low signal intensity area
($3 mm in size), depicted on T1-weighted images, that was
also visible as a hyperintense lesion on T2-weighted images
(Fig. 1). The number and location of SCIs in the territory
of the carotid artery system were assessed in each subject.
All SCIs detected were lacunar infarcts ,15 mm. We
classified the asymptomatic hypertensive subjects studied
into the three following subgroups, based on the number of
SCIs: 1) noninfarct group with no SCI; 2) few infarct group
with one or two SCIs per person; and 3) multiple infarct
group with three or more SCIs per person (10). The
location of SCIs was divided into the following two sub-
types: 1) subcortical white matter infarct; and 2) basal
ganglia infarct (head of caudate, putamen, pallidum and
thalamus). All of the MRIs were interpreted in a blinded
manner, and classification of the patients was done before
the blood testing.
Abbreviations and Acronyms
AUC 5 area under the curve
EC 5 endothelial cell
ELISA 5 enzyme-linked immunosorbent assay
F112 5 prothrombin fragment 112
MRI 5 magnetic resonance imaging
OGTT 5 75-g oral glucose tolerance test
PAI-1 5 plasminogen activator inhibitor-1
PIC 5 plasmin-alpha2-plasmin inhibitor complex
SCI 5 silent cerebral infarct
TAT 5 thrombin-antithrombin complex
t-PA 5 tissue-type plasminogen activator
vWF 5 von Willebrand factor
Figure 1. Brain MRI findings (T2-weighted images) of silent multiple
lacunar infarcts. The top images show lacunar infarcts (arrows) in the basal
ganglia, and the lower images show those infarcts (arrows) in the deep
white matter. Cerebral infarcts were defined exclusively as a low signal
intensity area (3 to 15 mm in size), depicted on T1-weighted images, that
was also visible as a hyperintense lesion on T2-weighted images. MRI 5
magnetic resonance imaging.
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Ambulatory Blood Pressure
Monitoring and Electrocardiography
Noninvasive ambulatory blood pressure monitoring was
carried out on a weekday using an automatic system with
gas-powered cuff inflation (ABPM-630, Nippon Colin Co.,
Komaki, Japan), which recorded blood pressure and heart
rate every 30 min for 24 h (11). In five patients, the initial
blood pressure data were rejected because of artifacts in
.10% of the total measurements; however, the examination
was repeated, and the second set of blood pressure data was
included in the analysis. Left ventricular hypertrophy, as
shown by electrocardiography, was defined as abnormally
high QRS voltages (R wave in lead V5 plus S wave in lead
V1 $3.5 mV) associated with either flat T waves (,10% of
R wave) or ST segment depression (.0.1 mV) and biphasic
T waves.
Sample Collection
Blood samples were obtained between 9 AM and 10 AM after
an overnight fast on the same day that the OGTT was
performed. Specimens for the assay of coagulation variables
were collected by the two-syringe method into disposable
siliconized vacuum glass tubes containing a 1/10 volume of
3.8% trisodium citrate. The samples were centrifuged at
3,000 g for 15 min at room temperature. After separation,
the serum samples for lipids were stored at 4°C in refriger-
ated containers if the analysis was not performed within the
next few days. The sample for coagulation and insulin assays
was subsequently separated and stored in several plastic
tubes at 280°C until laboratory tests were performed.
Oral Glucose Tolerance-Test
For the OGTT, a 75-g glucose load was administered after
a 12-h overnight fast. Blood was drawn immediately before
ingestion and 30, 60 and 120 min after the glucose load.
The area under the curve (AUC) of the plasma glucose–
time plot (2-h glucose AUC) and that of the insulin–time
plot (2-h insulin AUC) were calculated.
Assay Procedure
Plasma fibrinogen levels were determined using a one-stage
clotting assay kit (Data-Fi, Dade, Florida) (12). The plasma
levels of PAI-1, t-PA–PAI-1 complex, plasmin-alpha2-
plasmin inhibitor complex (PIC), thrombin–antithrombin
complex (TAT), prothrombin fragment 112 (F112) and
D-dimer were determined using commercially available
enzyme-linked immunosorbent assay (ELISA) kits for
PAI-1 (Biopool, Sweden), t-PA–PAI-1 complex and PIC
(Teijin Co. Inc., Tokyo, Japan), F112 and TAT (Behring-
werke AG, Marburg, Germany) and D-dimer (Diagnostica
Stago, Asnie`res, France). The plasma level of von Wille-
brand factor (vWF) was measured by using the recently
developed ELISA kit (Shield Diagnostics Ltd., Dundee,
United Kingdom) using monoclonal antibody against the
functional epitope of vWF (13), and the value for commer-
cially available pooled plasma (CTS Standard Plasma,
Behringwerke AG, Germany) was taken as 100%. Serum
insulin was determined by a radioimmunoassay kit (Phar-
macia & Upjohn Diagnostics AB, Uppsala, Sweden).
Statistical Analysis
All analyses were conducted with SPSS/Windows, version
8.0J (SPSS Inc.). The mean values and proportions were
calculated for background variables. Geometric mean val-
ues 6 SD were calculated for triglycerides, insulin, glucose,
vWF, PAI-1, t-PA–PAI-1 complex, PIC, F112, TAT,
D-dimer and fibrinogen levels owing to skewed distribution
of the variables. After one-way analysis of variance, the
Scheffe´ F test was used for comparisons of continuous
variables among the groups. The unpaired t test was used for
comparisons of continuous variables between the two
groups. The chi-square or Fisher exact test was used for
calculating proportions. Pearson correlation coefficients
were used to measure correlations between continuous
variables. Adjusted odds ratios with 95% confidence inter-
vals for no or low SCI (0 5 those with no infarct; 1 5 those
with one or more infarcts) and for multiple SCIs (0 5 those
with ,3 infarcts; 1 5 those with $3 infarcts) were
calculated by using multiple logistic regression analysis with
selected independent variables. To study the relationship
between the location of the SCI and cardiovascular risk
factors, we conducted multiple logistic analysis with white
matter infarction (0 5 those with no infarct and those with
only a basal ganglia infarct; 1 5 those with a white matter
infarct both with and without a basal ganglia infarct) or
basal ganglia infarction (0 5 those with no infarct and those
only with a white matter infarct; 1 5 those with a basal
ganglia infarct both with and without a white matter infarct)
as the dependent variable. Two-tailed tests were used, and p
values ,0.05 were considered significant.
RESULTS
Clinical Variables and SCI of Study Subjects
The mean 6 SD clinical blood pressure levels of the total
study group were 169 6 22 mm Hg systolic and 97 6
15 mm Hg diastolic, and the mean 24-h blood pressure
levels were 144 6 15 mm Hg systolic and 81 6 11 mm Hg
diastolic. Of the 123 study subjects 93% had hypertension
according to the criteria of the American Society of Hyper-
tension (14). The prevalence of total SCI was 65% (n 5 80),
and that of multiple SCIs was 39% in the total study group.
Table 1 shows the characteristics of the 123 subjects
separated into three groups according to the number of
SCIs. The age was older and the 24-h systolic blood
pressure was significantly higher in the total infarct group
and in the multiple infarct group than in the noninfarct
group, although there were no significant differences in
clinical blood pressure levels between the three groups. The
prevalence of smokers and left ventricular hypertrophy
tended to be higher in the total infarct and multiple infarct
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groups, although these did not reach statistical significance.
The lipid profile was not different between the three groups.
Insulin and Glucose Profiles of OGTT
The 2-h insulin levels were significantly higher in the few
infarct and multiple infarct groups than in the noninfarct
group, and the 2-h insulin AUC was also higher in the
multiple infarct group than in the noninfarct group or the
few infarct group (Table 2). There were no significant
differences in these insulin profiles between the noninfarct
group and few infarct group. The glucose profiles were not
different between the three groups.
Hemostatic Profiles
The levels of vWF, PAI-1, F112, TAT and D-dimer were
significantly higher in the total infarct and multiple infarct
groups than in the noninfarct group (Table 2). The vWF
and PAI-1 levels were also higher in the multiple infarct
group than in the few infarct group.
Association Between Insulin
Profiles and Hemostatic Profiles
The 2-h insulin AUC was negatively correlated with high
density lipoprotein cholesterol (r 5 20.25, p , 0.01) and
positively correlated with triglycerides (r 5 0.24, p , 0.01),
vWF (r 5 0.25, p , 0.01), PAI-1 (r 5 0.28, p , 0.01) and
t-PA–PAI-1 complex (r 5 0.25, p , 0.01). The fasting
insulin level and 2-h insulin level had similar trends in their
relationships with these factors. The 2-h insulin AUC
tended to be negatively correlated with the PIC level (r 5
20.15, p , 0.07). The plasma PAI-1 level was negatively
correlated with the PIC level (r 5 20.22, p , 0.02).
Table 1. Characteristics of Hypertensive Subjects With and Without a Silent Cerebral Infarct
Variables
Noninfarct Group
(n 5 43)
Total Infarct Group
(n 5 80)
Few Infarct Group
(n 5 32)
Multiple Infarct Group
(n 5 48)
Age (yrs) 66 6 6.0 70 6 7.9* 69 6 7.6 71 6 8.0*
Male 28% 31% 25% 35%
Body mass index (kg/m2) 23.9 6 3.6 24.4 6 3.7 24.5 6 4.3 24.3 6 3.3
Clinical SBP (mm Hg) 167 6 20 170 6 22 169 6 21 172 6 23
Clinical DBP (mm Hg) 97 6 13 98 6 15 97 6 17 98 6 14
24-h SBP (mm Hg) 140 6 13 146 6 16† 142 6 17 149 6 14†
24-h DBP (mm Hg) 80 6 10 81 6 12 81 6 12 82 6 12
Smokers 30% 34% 28% 37%
ECG-LVH 14% 24% 22% 25%
Hematocrit 0.40 6 0.03 0.40 6 0.04 0.40 6 0.04 0.40 6 0.03
Total cholesterol (mmol/liter) 5.5 6 0.6 5.2 6 0.9 5.1 6 0.8 5.3 6 1.0
HDL cholesterol (mmol/liter) 1.3 6 0.3 1.2 6 0.3 1.1 6 0.3 1.2 6 0.3
Triglycerides (mmol/liter) 1.5 (0.9–2.6) 1.5 (0.9–2.5) 1.4 (0.9–2.2) 1.6 (0.9–2.7)
*p , 0.01 and †p , 0.05 versus noninfarct group. The difference between the noninfarct group and the total infarct group was tested by using the unpaired t test. The differences
between the noninfarct, few infarct and multiple infarct groups were tested by using the Scheffe´ F test after analysis of variance. The total infarct group was the combined group
of the few infarct and multiple infarct groups; subjects with no cerebral infarct on brain magnetic resonance imaging were classified as the noninfarct group; subjects with one
or two infarcts comprised the few infarct group; and subjects with three or more infarcts comprised the multiple infarct group. Data are presented as the mean value 6 SD or
the prevalence of other risk factors, except for triglycerides, expressed as the geometric mean value (SD range).
DBP 5 diastolic blood pressure; ECG-LVH 5 left ventricular hypertrophy detected by electrocardiography; HDL 5 high density lipoprotein; SBP 5 systolic blood pressure.
Table 2. Insulin Profiles and Hemostatic Factors in Hypertensive Subjects
Variables
Noninfarct Group
(n 5 43)
Total Infarct Group
(n 5 80)
Few Infarct Group
(n 5 32)
Multiple Infarct Group
(n 5 48)
Fasting plasma glucose (mmol/liter) 5.3 (4.1–6.1) 5.5 (4.8–6.2) 5.6 (4.9–6.3) 5.4 (4.8–6.1)
2-h plasma glucose (mmol/liter) 6.4 (5.0–9.8) 6.8 (4.8–9.6) 6.9 (4.9–9.8) 6.7 (4.7–9.5)
Fasting insulin (mmol/liter) 35 (25–50) 39 (28–59) 41 (28–60) 38 (25–58)
2-h plasma insulin (mmol/liter) 132 (66–252) 184 (90–376)† 174 (84–360) 192 (96–390)‡
2-h glucose AUC (pmol/liter per min) 7.4 (5.9–9.2) 7.9 (6.2–10) 8.1 (6.2–11) 7.8 (6.2–9.9)
2-h insulin AUC (pmol/liter per min) 159 (108–237) 184 (105–322) 153 (84–276) 207 (126–345)‡§
vWF (%) 138 (108–177) 171 (134–218)* 157 (122–203) 180 (144–225)*§
PAI-1 (mg/liter) 39 (21–72) 54 (28–104)† 42 (24–73) 64 (33–124)*§
t-PA–PAI-1 (mg/liter) 11 (7.1–16) 13 (7.7–21) 13 (8.2–21) 13 (7.2–21)
PIC (mg/liter) 1.2 (0.8–1.8) 1.4 (1.0–2.0) 1.4 (1.0–2.1) 1.4 (1.0–2.0)
F112 (nmol/liter) 1.3 (0.8–2.2) 1.6 (1.1–2.5)‡ 1.5 (1.0–2.1) 1.7 (1.1–2.7)‡
TAT (mg/liter) 1.7 (1.1–2.9) 2.3 (1.4–4.0)† 2.0 (1.2–3.5) 2.6 (1.5–4.4)†
D-dimer (mg/liter) 184 (111–305) 291 (140–606)* 275 (158–479)‡ 302 (131–695)†
Fibrinogen (g/liter) 2.66 (2.01–3.44) 2.88 (2.34–3.54) 2.82 (2.31–3.44) 2.91 (2.36–3.61)
*p , 0.01; †p , 0.01. ‡p , 0.05 versus noninfarct group; §p , 0.05 versus few infarct group. The difference between the noninfarct group and the total infarct group was tested
by using the unpaired t test. The differences between the noninfarct, few infarct and multiple infarct groups were tested by using the Scheffe´ F test after analysis of variance. For
the definitions of the total infarct, noninfarct, few infarct and multiple infarct groups, see Table 1. Data are expressed as the geometric mean value (SD range).
AUC 5 area under the curve (during the oral glucose tolerance test); F112 5 prothrombin fragment 112; PAI-1 5 plasmin activator inhibitor-1; PIC 5
plasmin-alpha2-plasmin inhibitor complex; t-PA–PAI-1 5 tissue-type plasminogen activator–PAI-1 complex; TAT 5 thrombin–antithrombin complex; vWF 5 von Willebrand
factor.
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Multiple SCIs Versus Any SCIs
Multiple logistic regression analysis was conducted using
the factors that were significantly higher in the total infarct
and multiple infarct groups than in the noninfarct group, as
shown in Tables 1 and 2, as the independent variables
(Tables 3 and 4). Only age and 2-h insulin AUC were
significantly and independently associated with the end
point of (any) SCI. However, for the end point of multiple
SCIs, the list of variables showing a statistically significant
independent association included age, 24-h systolic blood
pressure, vWF, PAI-1 and F112, but not 2-h insulin AUC.
Location of SCIs
Of the 80 subjects with one or more SCIs, 35 (44%) had
infarcts only in the white matter, 25 (31%) had them only in
the basal ganglia and 22 (28%) had infarcts in both. In the
separate analysis of subtypes according to location (Table 4),
we found that a white matter infarct was independently
associated with aging and 2-h insulin AUC, and a basal
ganglia infarct was independently associated with PAI-1
and D-dimer levels. When smoking and lipid profiles (total
cholesterol, high density lipoprotein cholesterol and triglyc-
erides) were selected as independent variables for each
model, these variables were not related to either white
matter or basal ganglia infarcts (data not shown).
DISCUSSION
Several novel findings emerged from our study of Japanese
elderly hypertensive subjects. We found that hyperinsulin-
emia was associated with lacunar SCIs detected by brain
MRI, particularly those located in the white matter. Fur-
thermore, we found that hemostatic abnormalities were
associated with multiple SCIs, particularly those located
with the basal ganglia.
Prevalence of SCIs and Their Location
In this study, the prevalence of SCIs in the total study group
was 65%. In a previous study, one or more SCIs were
detected in 14 (41%) of 34 normotensive, healthy, elderly
subjects recruited from a Japanese community (10). In the
previous MRI studies of high risk elderly Japanese subjects,
the prevalence of SCI was ;50% (10,15,16). In our present
study, the prevalence of SCI (65%) was slightly higher than
these previous results. This may be due to higher blood
pressure levels in our group as compared with others.
According to the criteria of the American Society of
Hypertension, 93% of our study group had hypertension in
which both clinical and ambulatory blood pressures were
high. In a previous MRI study of 219 Japanese adults (mean
age 63 years, 64% men) with no history of stroke or
transient ischemic attack who visited a neurologic depart-
ment, the investigators detected one or more SCIs in 88
subjects (40%), and the distribution was as follows: 50 (57%)
had white matter infarcts, 6 (6.8%) had only basal ganglia
infarcts and 32 (36%) had both (17). In our study, of the 80
subjects with one or more SCIs, 35 (44%) had infarcts only
in the white matter, 25 (31%) had them only in the basal
ganglia and 22 (28%) had SCIs in both. The basal ganglia
infarcts were more common, and white matter infarcts were
less common in our group, as compared with the previous
study.
Table 3. Multiple Logistic Regression Analysis With All Silent
Cerebral Infarcts or Silent Multiple Cerebral Infarcts as the
Dependent Variable in Hypertensive Subjects
Variables
All Cerebral
Infarcts (n 5 80)
Multiple Cerebral
Infarcts (n 5 48)
Age (10-yr groups) 2.9 (1.4–6.1)† 4.1 (1.5–9.0)†
Male 2.2 (0.80–6.6) 3.2 (0.87–12)
24-h SBP (10 mm Hg) 1.3 (0.98–1.8) 1.6 (1.2–2.3)†
2-h insulin AUC 8.1 (1.3–50)‡ 3.1 (0.66–14)
vWF 1.5 (0.32–7.0) 5.7 (1.2–27)‡
PAI-1 2.7 (0.80–9.5) 13 (3.5–51)*
F112 1.3 (0.43–4.1) 5.6 (1.6–20)†
TAT 1.5 (0.52–4.5) 0.89 (0.28–2.9)
D-dimer 7.1 (0.82–61) 4.0 (0.97–16)
*p , 0.001; †p , 0.01; ‡p , 0.05. The adjusted odds ratios (95% confidence
intervals) for silent cerebral infarcts (0 5 subjects with no infarct; 1 5 subjects with
one or more infarcts) or for silent multiple cerebral infarcts (0 5 subjects with less
than three infarcts; 1 5 subjects with three or more infarcts) were calculated by using
multiple logistic regression analysis. The analyses of 2-h insulin area under the curve
(AUC), von Willebrand factor (vWF), plasmin activator inhibitor-1 (PAI-1),
prothrombin fragment 112 (F112), thrombin–antithrombin complex (TAT) and
D-dimer were based on the following coding: 0 5 less than the geometric mean
value 6 1 SD; 1 5 greater than or equal to the geometric mean value 6 1 SD. The
geometric mean values 6 1 SD were 291 pmol/liter per min for 2-h insulin AUC,
207% for vWF, 93 mg/liter for PAI-1, 2.4 nmol/liter for F112; 3.6 mg/liter for TAT
and 497 mg/liter for D-dimer.
SBP 5 systolic blood pressure.
Table 4. Multiple Logistic Regression Analysis of Silent
Subcortical Cerebral Infarcts or Silent Basal Ganglia Infarcts as
the Dependent Variable in Hypertensive Subjects
Variables
White Matter
Infarct (n 5 57)
Basal Ganglia
Infarct (n 5 47)
Age (10-yr groups) 2.3 (1.2–4.2)* 1.1 (0.63–2.1)
Male 1.7 (0.67–4.5) 1.7 (0.64–4.4)
24-h SBP (10 mm Hg) 1.1 (0.83–1.4) 1.2 (0.63–2.1)
2-h insulin AUC 4.2 (1.1–16)† 0.98 (0.27–3.5)
vWF 1.1 (0.33–3.9) 2.4 (0.68–8.4)
PAI-1 2.2 (0.82–5.9) 2.8 (1.0–7.6)†
F112 2.3 (0.85–6.3) 0.46 (0.15–1.4)
TAT 1.2 (0.47–2.9) 1.8 (0.71–4.5)
D-dimer 1.2 (0.34–3.9) 4.0 (1.1–14)†
*p , 0.01. †p , 0.05. The adjusted odds ratios (95% confidence intervals) for a
subcortical white matter infarct (0 5 subjects with no infarct and those with only a
basal ganglia infarct; 1 5 those with a white matter infarct both with and without a
basal ganglia infarct) or for a basal ganglia infarct (0 5 subjects with no infarct and
those with only a white matter infarct; 1 5 subjects with a basal ganglia infarct both
with and without a white matter infarct) were calculated by using multiple logistic
regression analysis with selected independent variables. The analyses of 2-h insulin
area under the curve (AUC), von Willebrand factor (vWF), plasmin activator
inhibitor-1 (PAI-1), prothrombin fragment 112 (F112), thrombin–antithrombin
complex (TAT) and D-dimer were based on the following coding: 0 5 less than the
geometric mean value 6 1 SD; 1 5 greater than or equal to the geometric mean
value 6 1 SD. The geometric mean values 6 1 SD were 291 pmol/liter per min for
2-h insulin AUC, 207% for vWF, 93 mg/liter for PAI-1, 2.4 nmol/liter for F112, 3.6
mg/liter for TAT and 497 mg/liter for D-dimer. Basal ganglia infarcts include infarcts
of the caudate, putamen, globus pallidum and thalamus.
SBP 5 systolic blood pressure.
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Association of Hyperinsulinemia with SCIs
In the present study, all SCIs were lacunar infarcts ,15 mm
in size, indicating that hyperinsulinemia may be related to
small-vessel disease. In previous studies of insulin levels or
underlying insulin resistance and symptomatic lacunar in-
farction, the results were inconsistent (18,19). One study
found that fasting plasma insulin levels were higher in the
lacunar stroke group than in the large-vessel disease group
and the control group (18), whereas another study found
that only the atherothrombotic stroke group had a higher
insulin resistance (directly determined by the steady state
plasma glucose method) and 2-h insulin AUC during
OGTT, as compared with the lacunar stroke, cardioembolic
stroke and control groups (19). The hemodynamic effect
may also be a confounding factor that may explain the
positive relationship between hyperinsulinemia and SCI. In
one previous study, the intima-medial thickness of the
carotid artery was positively associated with hyperinsulin-
emia (20). Advanced atherosclerosis and the related increase
in stiffness of the large artery may cause enhanced fluctua-
tion of cerebral blood flow in the marginal arteries.
Association Between
Hyperinsulinemia and Hemostatic Abnormalities
Insulin profiles (fasting insulin, 2-h insulin and/or 2-h
insulin AUC) were associated positively with plasma levels
of PAI-1, other EC-derived factors (vWF and t-PA–PAI-1
complex) and triglycerides, and negatively with the high
density lipoprotein cholesterol level. These factors may be
confounding factors that may partly explain the relationship
between hyperinsulinemia and SCI in hypertensive subjects.
In previous studies of normal subjects (both younger and
older) and patients with atherosclerotic disease, there was a
positive association between insulin levels and these cardio-
vascular and hemostatic variables blood pressure, triglycer-
ides and PAI-1) (3,4). In an in vivo study of rabbits, infusion
of insulin or proinsulin increased plasma PAI-1 activity and
gene PAI-1 expression in the aorta and liver (21).
Association of Hemostatic Abnormalities with SCIs
Among hemostatic risk factors for SCI in hypertensive
patients, the plasma PAI-1 level was the strongest. In a
previous report on hemostatic activation in clinically overt
ischemic stroke, PAI-1 and t-PA levels were increased in
both the early and late phases (22). According to the
Oxfordshire Community Stroke Project classification, the
PAI-1 and t-PA levels in patients with lacunar infarction
were comparable to those of the patients with cortical
infarction (22). In our study, the plasma PAI-1 level was
negatively associated with the level of PIC (an indicator of
plasmin generation), which tended to be negatively associ-
ated with the insulin profile. This suggests in vivo suppres-
sion of PAI-1 in plasmin generation, which is consistent
with previous results found in healthy older subjects (4).
When thrombin generation occurs in vivo, t-PA is simul-
taneously released to induce plasmin generation. This sec-
ondary fibrinolysis could act against increased thrombin
generation. In the multiple infarct group, both thrombin-
generation markers (F112 and TAT) were increased, but
the PIC level was not increased, as compared with those
levels in the noninfarct group. This imbalance between
thrombin-generation and plasmin-generation may acceler-
ate microatherothrombosis formation in small arteries, cre-
ating multiple lacunar infarcts, even in the silent stage of
hypertensive cerebrovascular disease. In addition, t-PA in
cerebrovascular endothelium may be related to the forma-
tion of a silent lacunar infarct. A recent study using
immunohistochemistry and Western blotting disclosed that
t-PA-containing vessels are mainly distributed in the
smaller vessels (precapillary arterioles and postcapillary
venules) in several stroke-prone regions of rat brains, which
are often used to study the pathophysiologic consequences
of cerebral ischemia (23). Thus, stroke-prone subjects may
also be protected against high PAI-1 levels for developing
small-vessel disease (lacunar infarct). However, once ECs in
the small vessels are damaged due to aging or hypertension,
or both, the effect of high plasma PAI-1 levels might be
overt, as found in the present study.
We also found that higher plasma levels of vWF, which
is synthesized and secreted from ECs, were associated with
multiple SCIs. The vWF-mediated platelet adhesion to the
injured endothelium is the first step in thrombus formation.
The specific ELISA kit used in this study uses the mono-
clonal antibody to the functional epitope of vWF (12),
whereas previous commercially available ELISA kits use the
polyclonal antibody. Although various conditions such as
EC damage, hypertension, diabetes, systemic atherosclero-
sis and inflammation (9,24) could increase plasma vWF
levels, the increase in the functional vWF levels detected by
this new ELISA kit may potentially lead to acceleration of
microthrombus formation in multiple SCIs in elderly hy-
pertensive subjects.
Risk Factors and Multiple SCIs
In the present study, there were no significant differences in
hemostatic abnormalities between the low infarct group and
the noninfarct group. The only significant difference was
found in the multiple infarct group. Thus, hemostatic
abnormalities may not be important in patients with only a
few infarct formations, but these abnormalities may more
often affect the larger-sized cerebral arteries, the branches of
which end terminal cerebral arteries. In addition, multiple
logistic analysis revealed that multiple infarcts were signif-
icantly independently associated with age, 24-h systolic
blood pressure, vWF, PAI-1 and F112, but not with the
insulin profile. Thus, hemostatic abnormalities may have
some further impact, leading to the development of multiple
lacunar infarcts, and may not be linked at all to hyperinsu-
linemia and insulin resistance.
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Risk Factors and Location of SCIs
When we analyzed subtypes according to the location of
SCI, we found that white matter infarcts were indepen-
dently associated with age and 2-h insulin AUC, and basal
ganglia infarcts were associated with PAI-1 and D-dimer.
These results suggest that basal ganglia infarcts may be more
closely related to systemic atherosclerosis and impaired
hemostasis, because a recent report disclosed that the early
stage of carotid atherosclerosis (intimal-medial thickening,
as assessed by B-mode ultrasound) is positively associated
with levels of PAI-1, t-PA and D-dimer in a population-
based study (25). Thus, the progress of intracranial or
extracranial atherosclerosis may explain the positive associ-
ation between these fibrinolytic factors and SCI, especially
in the basal ganglia, in older hypertensive subjects. In
contrast, white matter infarcts may be more closely related
to age-related arteriosclerosis of small perforating arteries.
In addition, the 2-h insulin AUC was also independently
associated with this subtype. Lipid profiles and smoking
were related to neither subtype. However, in this study
group, 28% of the patients had SCIs in both the white
matter and basal ganglia. Thus, interpretation of the results
is limited.
Study Limitations
The number of study subjects was relatively small, and this
study was cross-sectional. In addition, there are racial and
demographic differences in cardiovascular disease. Coronary
artery disease is markedly less common, but stroke, partic-
ularly lacunar infarction, is slightly more common, in Japan
than in Western countries. Thus, generalizability of our
evidence found in elderly Japanese subjects (who continue
the traditional Japanese lifestyle) should be tested in a larger,
prospective study with subjects from different parts of the
world.
Conclusions
In asymptomatic elderly hypertensive subjects, hyperinsu-
linemia appears to be associated with lacunar SCIs, partic-
ularly those located in the subcortical white matter. Hemo-
static abnormalities showed an association with the presence
of multiple lacunar infarcts, particularly those located in the
basal ganglia.
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